At ASCO, Blueprint presented positive data on its RET inhibitor pralsetinib across a range of cancers and in a call with investors discussed regulatory plans in lung and thyroid cancers.
The gap in care suggests that more education and decision support tools are needed to help physicians prescribe drugs based on highly actionable tumor alterations, researchers said.
The agency made its decision based on the SOLAR-1 study showing a five-month progression-free survival benefit for Piqray plus fulvestrant over just fulvestrant.
Two studies presented at ASCO's virtual annual meeting demonstrated the clinical utility of germline findings in guiding treatment decisions in cancer.
Results show population screening can pick up risky BRCA1/2 mutations in men and women from Ashkenazi Jewish populations in the US, though engagement challenges remain.
The company will start Phase I/II trials to evaluate the safety and anti-tumor activity of its natural killer cells in combination with Herceptin or Erbitux in the third quarter of 2020.
